Article citationsMore>>

H. C. Gerstein, J. F. Mann, Q, Yi, B. Zinman, S. F. Dinneen, B. Hoogwerf, J. P. Hallé, J. Young, A. Rashkow, C. Joyce, S. Nawaz and S. Yusuf; HOPE Study Investigators, “Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals,” JAMA, Vol. 286, No. 4, 2001, pp. 421-426. doi:10.1001/jama.286.4.421

has been cited by the following article:

• TITLE: Amelioration of Albuminuria in Japanese Type 2 Diabetic Patients by Maximal Dose of Candesartan

  AUTHORS: Yoichi Oikawa, Akira Shimada, Mizumi Kyo

  KEYWORDS: Albuminuria; Angiotensin II Receptor Blocker (ARB); Candesartan; Hypertension; Type 2 Diabetes

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.3 No.5, September 20, 2013

  ABSTRACT: Introduction: It was recently reported that candesartan, an angiotensin II receptor blocker, had a protective effect against cardiovascular events, comparable to that of calcium channel antagonists. Moreover, a renoprotective effect and anti-diabetic action of candesartan had also been demonstrated. However, whether the renoprotective effect of candesartan, especially in diabetes, was dose-dependent or not remain to be fully elucidated. The present study attempted to clarify the dose effect of renoprotection by candesartan in Japanese type 2 diabetic patients. Subjects and Method: In this case series study, we recruited 26 type 2 diabetic patients with albuminuria whose blood pressure did not reach the target BP level ( were increased to the maximal dose in Japan, 12 mg/day. Clinical parameters were examined before, at 6 and 12 months after the increase in dose. Results: An ameliorating effect of the increased dose of candesartan on albuminuria and hypertension was distinctly observed. No severe adverse effect was observed. Conclusion: It was highly possible that the maximal dose of candesartan provided more effective renoprotection in hypertensive type 2 diabetic patients initially treated with lower doses of candesartan.